Activation of the ubiquitin-proteasome system in doxorubicin cardiomyopathy.
about
The tell-tale heart: molecular and cellular responses to childhood anthracycline exposureDissecting the Mechanisms of Doxorubicin and Oxidative Stress-Induced Cytotoxicity: The Involvement of Actin Cytoskeleton and ROCK1Perturbation of cullin deneddylation via conditional Csn8 ablation impairs the ubiquitin-proteasome system and causes cardiomyocyte necrosis and dilated cardiomyopathy in mice.Effects of short-term endurance exercise training on acute doxorubicin-induced FoxO transcription in cardiac and skeletal muscle.Loss of urokinase receptor sensitizes cells to DNA damage and delays DNA repairApoptosis in Anthracycline CardiomyopathyDoxorubicin acts via mitochondrial ROS to stimulate catabolism in C2C12 myotubesProteostasis and REDOX state in the heart.The regulatory mechanisms of myogenin expression in doxorubicin-treated rat cardiomyocytesHECT-Type Ubiquitin E3 Ligase ITCH Interacts With Thioredoxin-Interacting Protein and Ameliorates Reactive Oxygen Species-Induced Cardiotoxicity.Doxorubicin attenuates CHIP-guarded HSF1 nuclear translocation and protein stability to trigger IGF-IIR-dependent cardiomyocyte death.The role of the proteasome in heart diseaseMechanisms and management of doxorubicin cardiotoxicity.Proteotoxicity and cardiac dysfunction.Visfatin mediates doxorubicin resistance in human non-small-cell lung cancer via Akt-mediated up-regulation of ABCC1.Mitochondria: Inadvertent targets in chemotherapy-induced skeletal muscle toxicity and wasting?Effects of doxorubicin cancer therapy on autophagy and the ubiquitin-proteasome system in long-term cultured adult rat cardiomyocytes.Analysis of defective protein ubiquitylation associated to adriamycin resistant cells.Efficient monitoring of protein ubiquitylation levels using TUBEs-based microarrays.Hypoxia can impair doxorubicin resistance of non-small cell lung cancer cells by inhibiting MRP1 and P-gp expression and boosting the chemosensitizing effects of MRP1 and P-gp blockers.
P2860
Q26823592-F6805AA4-B67F-45A4-BEBF-AC46AFCB421FQ28546141-F5F55506-0306-40C2-B85D-96A2D60A2276Q34474447-E537BDC3-19F9-42DA-8DDC-544E1C4CBE8EQ35141318-F93BD808-638C-4EC2-992F-564396B339A2Q35200009-B6D68D6E-5D8C-4BF8-AE8F-CD534B6353C3Q35642302-A47CF661-7857-425E-9863-2E3C8D16A866Q35895750-3DFAFF9A-DA61-4C83-9C1D-3F3D813C8E9DQ35906430-6DF73C5D-7488-4B0E-A3CF-B7120264F62FQ36545773-9D56ABAA-CA55-4D1A-B5D6-E51673DB05A2Q36877602-1D25F954-5936-4950-8F29-12BA2A9F8310Q37603290-905AA7CC-CFAF-4F53-B1E9-9B4CED9EDA46Q37788836-343041C8-099E-4F01-8D81-41DCB37F9398Q38473474-5CE23EB9-85F4-4DCF-B1A2-DC52426462A2Q38497014-08D3735D-67D4-4330-B0C6-BA5C4681B70BQ38649748-9D3A291D-3DBE-47B3-AB3F-C23DB19B183DQ38831900-8D990322-D6FC-4532-ACE0-CB58F1302ADAQ41928716-2305DFB5-E7CA-44BF-9336-B05F26E2D4E7Q47445829-F51CD660-0EFB-41D3-BA75-E33CF1331065Q51644720-62F25A3B-001F-4880-853B-CA7ED236924BQ53083871-4239BC9D-9DC9-4976-B259-D54C7D066914
P2860
Activation of the ubiquitin-proteasome system in doxorubicin cardiomyopathy.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Activation of the ubiquitin-proteasome system in doxorubicin cardiomyopathy.
@ast
Activation of the ubiquitin-proteasome system in doxorubicin cardiomyopathy.
@en
type
label
Activation of the ubiquitin-proteasome system in doxorubicin cardiomyopathy.
@ast
Activation of the ubiquitin-proteasome system in doxorubicin cardiomyopathy.
@en
prefLabel
Activation of the ubiquitin-proteasome system in doxorubicin cardiomyopathy.
@ast
Activation of the ubiquitin-proteasome system in doxorubicin cardiomyopathy.
@en
P2860
P1476
Activation of the ubiquitin-proteasome system in doxorubicin cardiomyopathy
@en
P2093
Mark J Ranek
P2860
P2888
P304
P356
10.1007/S11906-009-0068-8
P50
P577
2009-12-01T00:00:00Z
P5875
P6179
1032499073